Regenstrief Research Scientist Noll Campbell, PharmD, M.S., has been voted president-elect of the American Delirium Society (ADS) by the board of directors. Dr. Campbell shall be installed into office at the side of the society’s national conference in June of 2023.

Delirium is a sudden change in brain function resulting in confusion and reduced awareness of an individual’s surroundings. People within the intensive care unit often experience delirium. 

Dr. Campbell’s research is targeted on the popularity and measurement of antagonistic cognitive effects of medicines in older adults with acute and chronic cognitive impairment, including delirium and dementia. This work includes the identification and implementation of tools and processes to mitigate the antagonistic cognitive effects of medicines. 

Delirium is an indication of acute brain dysfunction and more common in older adults. It has also been repeatedly related to long-term cognitive impairment and dementia. It complicates recovery from acute illness, and costs victims, their families and healthcare systems vast amounts of resources. Reducing these costs and complications of delirium would significantly improve the outlook of the aging population.”

Dr. Noll Campbell, PharmD, M.S.

Dr. Campbell maintains an energetic clinical practice as a geriatric pharmacotherapy expert inside Eskenazi Health, supporting the interpretation and implementation of his research into clinical care.

“I’m excited and gratified to be a component of this society and lead the charge toward eradicating delirium through continued research and collaboration with national and international partners committed to improving delirium science,” said Dr. Campbell. 

In his role because the society’s president, Dr. Campbell will oversee the society’s programs and guide resources to advance the mission of advocacy for patients and dissemination of research and best practices. 

Regenstrief Research Scientist Malaz Boustani, M.D., MPH, was the founding president of ADS. Babar Khan, M.D., M.S., one other Regenstrief research scientist, served because the 2019-2020 president. Each Drs. Campbell and Khan are current members of the ADS board of directors. 

The mission of ADS is to encourage research, education, quality improvement, advocacy and implementation science to diminish the influence of delirium on short- and long-term health and welfare of patients. 

Noll Campbell, PharmD, M.S.  

Along with his role as a research scientist at Regenstrief Institute, Noll Campbell, PharmD, M.S., is an adjunct associate professor of medication at Indiana University School of Medicine and an associate professor of pharmacy practice on the Purdue University College of Pharmacy.